Hashimoto’s thyroiditis

Hashimoto’s thyroiditis

Hashimoto's thyroiditis

Hashimoto’s thyroiditis

 

Hashimoto’s thyroiditis belongs to the Thyroid Diseases.

It usually appears as Hypothyroidism.

Hashimoto’s thyroiditis now belongs to the Autoimmune Diseases, due to the growth of Auto-antibodies against the thyroid gland.

Hashimoto’s Thyroiditis – Symptoms

The main symptom in Hashimoto’s thyroiditis is swelling of the thyroid gland. This bronchoculus (swelling), is developing slowly. Thyroid nodules may also appear. The bronchoculus is medium sized, has an uneven surface and a lusty and semi-hard composition.
The patient, could not get aware of the bronchoculus, if it doesn’t get too big. The same applies to the thyroid nodules. The thyroid gland is usually homogeneously inflated, but there may be an asymmetric swelling, in the form of a large nodule or hump, due to the superiority of pathological and anatomical processes, to a particular area of the thyroid.

Hashimoto’s thyroiditis, also shows symptoms of Hypothyroidism such as fatigue, drowsiness, memory impairment, dry skin, weight gain, etc.

The pathology of Hashimoto’s Thyroiditis involves intense lymphocyte infiltration, which completely destroys the physiological Thyroid architecture. Lymphoid follicles and germinal centers may form.

Follicular epithelial cells are often inflated and contain a basophilic cytoplasm.

Gland destruction causes the reduction of T3 and T4 thyroid hormones in the patient’s serum (blood) and the rise of TSH.

Initially, TSH can maintain a satisfactory hormonal synthesis, through the development of thyroid swelling or bronchoculus that it causes to the thyroid, impelling it to produce thyroid hormones. Often, however, the thyroid gland subfunctions and eventually Hypothyroidism follows, with or without a bronchoculus.

Hashimoto’s Thyroiditis – Treatment

The generalized view that there is no definitive treatment for Thyroid gland disorders, as for Hashimoto’s Thyroiditis (Disease), is wrong.

The usual administration of pharmaceutical preparations, has as a main purpose, to provide the body with the hormones it lacks, which it can no longer produce. This is achieved by administering synthetic thyroid hormones for decades now. In clinical practice, however, the patient is constantly deregulated. The change in the dosage of its hormones, is constantly required to treat his/her symptoms.

In addition, this cycle is infinite, with unfavorable results in everyday life, resulting to the burden of health and psychology of patients, who do not see their health levels being restored.

The key to a successful therapeutic approach is to find the causes.

Patients do not change their everyday life. Instead, they gradually see it getting improved, along with their overall physical health.

   – Without “special diets” and deprivation

   – Without taking chemical and pharmaceutical substances

   – Treatments that act individually or combined, without side effects

By blood sampling, tests are carried out by specialised Molecular Biopathological Laboratories. In this way, we can detect the factors that caused the disease (Hashimoto’s Thyroiditis) at a cellular level.

The total duration of the first visit is about one and a half hour and includes a specialized multi-page Personal Medical History, for all the body’s systems – Head to Toe, as well as patient’s nutritional habits and preferences.

After the neccessary biochemical, hormonal or specialized metabolic tests, any malfunctions are detected and all possible deficiencies are found.

The combination of regimens to regulate the Thyroid gland’s function at its ideal levels may include:

Micro-Macronutrients Treatments

Molecular Nutrition

Hormonal Replacement Therapy with Bioidentical Hormones.

Therapies are personalized, determined by algorithms in relation to laboratory findings, thorough individual history, lesions, and the existence of additional Chronic or other Diseases.

These specific therapies have been used in clinical practice since 1997, starting from the United States of America. They do not contradict with any parallel pharmaceutical or homeopathic treatment.

The appropriate treatment and nutrition is the one that ultimately results in the greatest benefit, according to the clinical results and the relevant test scores.

 

Dr. Nikoleta Koini, M.D.

Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine.

Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).

 

Read More


Functional Med System – F.M.S

Autoimmune Diseases

Hypothyroidism

 

 


References:

Heindal JJ, Endocrine disruptors and the obesity epidemic, Toxicol Sci 76; 2:247-49, 2003
Baillie  and Hamilton PF, Chemical toxins: a hypothesis to explain the global obesity epidemic, Jalt Complement Med 8 ; 2:185-92, 2002
Alonso-Magdalena P, et al, The estrogenic effect of bisphenol A disrupts pancreatic B-cell function in vivo and induces insulin resistance, Environ Health Perspect 114:106-12, 2006
The Hundred Year Diet in the Wall Street (May 10, 2010, A I5)
Vom Saal FS, Welshons WV, Large effects from small exposures. II. The importance of positive controls in low-dose research on bisphenol A, Environ Res, 100;1:50-76, Jan. 2006
Feige JN, et al, The endocrine disruptor monoethyl-hexyl phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis, JBiol Chem 282:19152-66, 2007
Hatch EE, et al., Association of urinary phthalate metabolite concentrations with a body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002, Environ Health 7:27, 2008
Altschul R, Hoffer A. The effect of nicotinic acid on hypercholesterolaemia.
Can Med Assoc J 1960; 82: 783-5. Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for Nacetyltransferase 2 with familial Parkinson’s disease. Lancet 1997;350:1136-1139.
Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40 Suppl 1: S49-51.
Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-97.
Biro S, Masuda A, Kihara T, and Tei C. Clinical implications of thermal therapy in lifestyle-related diseases. Exp Biol Med (Maywood). 2003 Nov; 228(10):1245-9.

 

ΚΑΛΕΣΤΕ ΜΑΣ ΤΩΡΑ